<DOC>
	<DOCNO>NCT01175291</DOCNO>
	<brief_summary>The purpose study efficacy ( effectiveness ) new drug , MK-0646 , metastatic colorectal cancer . MK-0646 investigational experimental anti-cancer agent yet approve U.S. Food Drug Administration ( FDA ) use metastatic colorectal cancer disease . This study ass whether add MK-0646 FDA-approved standard care chemotherapy improve participant ' duration progression-free survival . MK-0646 believe inhibit receptor protein call IGF-1 ( Insulin-like Growth Factor ) think contribute cancer development growth . However , guarantee MK-0646 slow cancer development growth . Other purpose study include : - look safety tolerability MK-0646 - compare MK-0646 + standard care chemotherapy placebo + standard care chemotherapy ( placebo substance look like active drug active ingredient ) The standard care chemotherapy study call FOLFOX 7 . FOLFOX 7 include drug oxaliplatin leucovorin , 5-Fluorouracil ( 5-FU ) , bevacizumab .</brief_summary>
	<brief_title>FOLFOX/Bevacizumab +/- MK-0646 Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Participants randomize ARM A receive modify FOLFOX 7 every week + MK-0646 every week : 5-FU 400 mg/m2 intravenous infusion 2-5 minute Leucovorin 400 mg/m2 intravenous infusion 2 hour Oxaliplatin 85 mg/m2 intravenous infusion 2 hour ( leucovorin ) Bevacizumab 5 mg/kg intravenous infusion 30 minute ( +/- 15 minute ) follow infusion may give 10 minute ( +/- 10 minute ) first infusion tolerate well . 5-FU 2400 mg/m2 continuous intravenous infusion 46 hour ( may deliver via automated outpatient pump ) Antiemetics ( drug prevent nausea vomit ) : 5-HT3 receptor antagonist ( e.g . ondansetron ) dexamethasone recommend prior chemotherapy . MK-0646 10 mg/kg intravenous infusion 60 minute every week ( participant large 100 kg [ 220 pound ] receive infusion 120 minute ) . Participants randomize ARM B receive modify FOLFOX 7 every week + placebo every week : 5-FU 400 mg/m2 intravenous infusion 2-5 minute Leucovorin 400 mg/m2 intravenous infusion 2 hour Oxaliplatin 85 mg/m2 intravenous infusion 2 hour ( leucovorin ) Bevacizumab 5 mg/kg intravenous infusion 30 minute ( +/- 15 minute ) ; follow infusion may give 10 minute ( +/- 10 minute ) first infusion tolerate well . 5-FU 2400 mg/m2 continuous intravenous infusion 46 hour ( may deliver via automated outpatient pump ) Antiemetics : 5-HT3 receptor antagonist ( e.g . ondansetron ) dexamethasone recommend prior chemotherapy Placebo intravenous infusion 60 minute every week ( participant large 100 kg [ 220 pound ] receive infusion 120 minute ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Metastatic colorectal adenocarcinoma . Measurable disease RECIST criterion . Adequate hepatic function : total bilirubin ≤2.0 x upper limit normal ( ULN ) ; Aspartate Amino Transferase ( AST ) /Alanine Amino Transferase ( ALT ) ≤3.0X upper limit normal ( ≤5X upper limit normal attributable liver metastasis ) . Adequate renal function : serum creatinine ≤2.0 mg/dl . Adequate bone marrow function : absolute neutrophil count ≥1,500/mm3 ; platelet ≥ 100,000/mm3 . Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) level ≤1.5 upper limit normal ( unless patient receive coumadin anticoagulation case stable international normalize ratio ( INR ) 23 require ) . Age ≥ 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Life expectancy ≥ 12 week . Negative pregnancy test . Ability sign inform consent . Prior systemic chemotherapy metastatic colorectal cancer Prior oxaliplatin adjuvant set within 12 month Uncontrolled central nervous system metastases carcinomatous meningitis . Myocardial infarction past 6 month . Major surgery within 8 week prior enrollment . Uncontrolled serious medical psychiatric illness . Inadequately control hypertension ( define systolic blood pressure &gt; 160mmHg , diastolic blood pressure &gt; 100mmHg ) . Pregnant lactating woman . Both men woman childbearing potential must advise importance use effective birth control measure course study . Prior experimental therapy target IGF1 pathway Concurrent malignancy ( exception squamous basal cell skin carcinoma ) Planned surgical metastasectomy Patient know hypersensitivity component treatment , analog , drug similar chemical biologic composition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>colon</keyword>
	<keyword>rectum</keyword>
	<keyword>colorectal</keyword>
	<keyword>metastatic</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>